Edgewise Therapeutics, Inc. EWTX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $33.21M-45.7% | $61.15M+32.9% | $46M+6.0% | $43.4M-13.1% | $49.92M+19.8% | ||
| $509.79M-6.2% | $543.39M-5.3% | $573.9M-4.9% | $603.26M+36.1% | $443.18M-6.8% | ||
| $7.4M-5.6% | $7.83M-3.7% | $8.13M-5.4% | $8.6M-4.4% | $8.99M-5.4% | ||
| $518.52M-6.2% | $552.6M-5.3% | $583.47M-4.9% | $613.33M+35.0% | $454.39M-6.7% | ||
| $7.29M+21.4% | $6.01M-2.5% | $6.16M-26.0% | $8.32M-5.3% | $8.79M+57.5% | ||
| $22.54M-17.6% | $27.37M+26.4% | $21.65M+3.6% | $20.9M-1.0% | $21.12M-11.5% | ||
| $25.32M-16.6% | $30.35M+22.3% | $24.82M+2.3% | $24.26M-1.7% | $24.67M-10.6% | ||
| $10K0.0% | $10K0.0% | $10K0.0% | $10K+11.1% | $9K0.0% | ||
| -$595.38M-9.0% | -$546.37M-10.1% | -$496.16M-8.9% | -$455.49M-8.6% | -$419.37M-10.8% | ||
| $493.2M-5.6% | $522.26M-6.5% | $558.65M-5.2% | $589.07M+37.1% | $429.72M-6.4% | ||
| $518.52M-6.2% | $552.6M-5.3% | $583.47M-4.9% | $613.33M+35.0% | $454.39M-6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Edgewise Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 22.61 — current assets exceed current liabilities.
- Where does Edgewise Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.